Abstract: Techniques for improving performance and quality in a market research platform include: obtaining first usage data of a first set of survey respondents to a first market research survey, the first market research survey being associated with a first tenant of a multi-tenant market research survey platform and conforming to a market research survey template provided by the platform; obtaining second usage data of a second set of survey respondents to a second market research survey, the second market research survey being associated with a second tenant of the platform and conforming to the market research survey template; generating a template-specific quality filter associated with the market research survey template, based at least on the first usage data and the second usage data; and based at least on the template-specific quality filter and third usage data of a particular survey respondent, identifying the particular survey respondent as a low-quality respondent.

Abstract: The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and/or inflammatory disease such as systemic lupus erythematosus (SLE), lupus nephritis, IgA nephropathy, other types of glomerulonephritis.

Abstract: The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and/or inflammatory disease such as systemic lupus erythematosus (SLE), lupus nephritis, IgA nephropathy, other types of glomerulonephritis.

Abstract: The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and/or inflammatory disease such as systemic lupus erythematosus (SLE), lupus nephritis, IgA nephropathy, other types of glomerulonephritis.

Abstract: During the progression of atherosclerosis, autoantibodies are induced to epitopes of oxidized low-density lipoprotein (OxLDL), and active immunization of hypercholesterolemic mice with OxLDL ameliorates athero-genesis. The present studies have identified anti-OXLDL autoantibodies that share complete genetic and structural identity with antibodies produced by anti-phosphorylcholine B-cell clone, T15.

Abstract: Provided are Staphylococcal protein A (SpA) variants for binding immunoglobulin (Ig), comprising a polypeptide which varies by one or more amino acids from the amino acid sequence of a natural variable heavy chain III (“VH3”) Ig-Fab binding region (“binding region”) of SpA, wherein the polypeptide exhibits a different binding specificity for Ig-Fab than does SpA or exhibits a different binding specificity for a non-Ig target molecule than does SpA. Further provided are methods of making the variants and methods of using the variants, as well as native SpA, for in purification of Ig as well as diagnostic and therapeutic intervention.